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Brief Definit ive Report
Medullary thymic epithelial cells (mTECs) con-
tribute to self-tolerance through the ectopic ex-
pression of tissue-specific antigens (TSAs) in the 
thymus (Derbinski et al., 2001; Anderson et al., 
2002; Metzger and Anderson, 2011). This TSA 
expression in mTECs is largely dependent on 
autoimmune regulator (Aire), which is expressed 
in mature mTECs (Gäbler et al., 2007; Gray et al., 
2007; Metzger and Anderson, 2011). Through 
the recognition of TSAs, developing autoreactive 
T cells are either negatively selected from the pool 
of developing thymocytes or recruited into the 
regulatory T (T reg) cell lineage (Liston et al., 2003; 
Anderson et al., 2005; DeVoss et al., 2006; Shum 
et al., 2009; Taniguchi et al., 2012; Malchow et al., 
2013). The overall importance of this process is 
underscored by the development of a multi-organ 
autoimmune syndrome in patients or mice with 
defective AIRE expression (Consortium, 1997; 
Nagamine et al., 1997; Anderson et al., 2002).
Although central tolerance provides pro-
tection against autoimmunity, this process also 
represents a challenge for anti-tumor immunity 
(Kyewski and Klein, 2006; Malchow et al., 2013). 
Because many of the TSAs expressed in the thy-
mus are also expressed in tumors, high-affinity 
effector T cells capable of recognizing tumor 
self-antigens may normally be deleted in the thy-
mus (Bos et al., 2005; Cloosen et al., 2007; Träger 
et al., 2012; Zhu et al., 2013). Transiently sup-
pressing central tolerance by depleting mTECs 
or modulating Aire expression may provide a 
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Thymic central tolerance is a critical process that prevents autoimmunity but also presents 
a challenge to the generation of anti-tumor immune responses. Medullary thymic epithelial 
cells (mTECs) eliminate self-reactive T cells by displaying a diverse repertoire of tissue-
specific antigens (TSAs) that are also shared by tumors. Therefore, while protecting against 
autoimmunity, mTECs simultaneously limit the generation of tumor-specific effector T cells 
by expressing tumor self-antigens. This ectopic expression of TSAs largely depends on 
autoimmune regulator (Aire), which is expressed in mature mTECs. Thus, therapies to 
deplete Aire-expressing mTECs represent an attractive strategy to increase the pool of 
tumor-specific effector T cells. Recent work has implicated the TNF family members RANK 
and RANK-Ligand (RANKL) in the development of Aire-expressing mTECs. We show that in 
vivo RANKL blockade selectively and transiently depletes Aire and TSA expression in the 
thymus to create a window of defective negative selection. Furthermore, we demonstrate 
that RANKL blockade can rescue melanoma-specific T cells from thymic deletion and that 
persistence of these tumor-specific effector T cells promoted increased host survival in 
response to tumor challenge. These results indicate that modulating central tolerance 
through RANKL can alter thymic output and potentially provide therapeutic benefit by 
enhancing anti-tumor immunity.
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has also demonstrated that mTECs in particular have a rela-
tively fast turnover in adult mice with an estimated half-life of 
2 wk (Gäbler et al., 2007; Gray et al., 2007). Given these find-
ings, we speculated that in vivo blockade of RANKL in adult 
hosts could both selectively and transiently inhibit the develop-
ment and turnover of mTECs with potential to alter central 
T cell tolerance. To this end, we performed in vivo RANKL 
blockade in adult mice and investigated its effects on both TECs 
and developing thymocytes. We show that anti-RANKL treat-
ment not only depleted mTECs but could also be used thera-
peutically to break central tolerance and, as a result, increase 
the generation of tumor-specific T cells.
RESULTS AND DISCUSSION
Depletion of mTECs with RANKL blockade
The RANK–RANKL signaling pathway is important for 
mTEC development, but it remains unclear what impact per-
turbation of this pathway might have on the adult thymus. 
Previous work has linked the RANK–RANKL pathway to 
the development of Aire-expressing mTECs (Rossi et al., 
2007; Akiyama et al., 2008; Hikosaka et al., 2008; Roberts 
et al., 2012), and we hypothesized that treating mice with 
blocking anti-RANKL antibody would decrease Aire+ mTECs. 
therapeutic window for the generation of T cells capable of 
recognizing tumor self-antigens. Many current cancer immune 
therapies rely on activating relatively weak tumor-specific T cell 
responses through modulating peripheral tolerance (Swann and 
Smyth, 2007; Chen and Mellman, 2013). In contrast, manipu-
lation of central tolerance has the potential to increase the 
pool and affinity of effector T cells that can recognize and con-
tribute to effective anti-tumor responses. Furthermore, such 
high-affinity, self-reactive T cells may be more resistant to pe-
ripheral tolerance mechanisms that typically restrain an anti-
tumor response (Swann and Smyth, 2007). Thus, the development 
of methods that selectively and transiently deplete Aire-expressing 
mTECs may be an attractive method to enhance tumor-specific 
immune responses.
Previous work has identified agents that can inhibit the 
growth and development of TECs such as corticosteroids, cy-
closporine, and some inflammatory cytokines (Anz et al., 2009; 
Fletcher et al., 2009). Despite their clear inhibitory effects on 
TECs, however, these agents do not appear to have selectivity 
for blocking mTEC development. Interestingly, recent studies 
have demonstrated a role for TNF family member pairs 
RANK–RANKL and CD40-CD40L in the embryological 
development of Aire+ mTECs (Rossi et al., 2007; Akiyama et al., 
2008; Hikosaka et al., 2008; Roberts et al., 2012). Recent work 
Figure 1. Selective depletion of mTECs with anti-
RANKL blockade. (A) Wild-type mice were treated for 2 wk 
with either isotype (gray) or anti-RANKL (RANKL, blue) 
antibody, and absolute numbers of mTECs and cTECs were 
enumerated by flow cytometry. Bar graphs of total cell num-
bers are depicted by mean ± SEM. (B) Representative flow 
cytometry plots of mTECs in A showing relative composition 
of mTEC subsets. Values represent mean ± SEM. Bar graphs 
(right) of total cell numbers of each mTEC subset depicted by 
mean ± SEM. (C) Top panels show immunostaining for keratin-8 
(green) and keratin-5 (red) on thymic sections, and bottom 
panels show immunostaining for keratin-5 (red) and  
Aire (green). Bars: (top) 500 µm; (bottom) 50 µm. (D) Gene 
expression analysis on mTECs sorted from wild-type mice 
treated with either isotype (gray) or anti-RANKL (blue) anti-
body. Results standardized to Cyclophilin A and normalized 
to isotype-treated mice with bars depicting mean ± SD.  
(E) Representative flow cytometry plots of thymocytes from 
antibody-treated wild-type mice. Values depict mean ± SD. 
Total thymocyte numbers (right) are indicated with each 
circle depicting an individual animal and bars showing the 
mean. (F) Flow cytometric analysis of Foxp3 staining in CD4 
SP thymocytes from E. Plots (right) show percentage and 
number of thymic CD4+ Foxp3+ cells, with bars showing the 
mean. Data shown in Fig. 1 is representative of two to four 
independent experiments containing three or more indi-
vidual mice within each group. *, P ≤ 0.05; ***, P ≤ 0.001, 
Student’s t test.
JEM Vol. 211, No. 5 763
Br ief Definit ive Repor t
corticomedullary thymic architecture despite these changes 
in TEC cellularity and mTEC composition (Fig. 2 D).
Collectively, these data suggest that RANK–RANKL–
OPG interactions regulate both TEC cellularity and mTEC 
maturation, and are particularly important for the induction of 
Aire+ mTECs. Furthermore, anti-RANKL treatment selec-
tively targeted mature mTECs and altered negative selection 
without affecting the development of new thymocytes.
Regeneration of mTECs after withdrawal of anti-RANKL
We next examined the kinetics of mTEC recovery after with-
drawal from anti-RANKL blockade. After a 2-wk treatment 
window, we harvested mice at 2-wk intervals and observed 
gradual recovery of the mTEChi and Aire+ subsets (Fig. 3, 
A and B). By 10 wk, we observed the complete recovery of 
all mTEC subsets and a normal level of Aire expression after 
anti-RANKL treatment (Fig. 3 B). Interestingly, the pattern of 
mTEC recovery appeared consistent with published reports 
of mTEClo cells giving rise to mTEChi cells before the induction 
of Aire+ mTECs (Fig. 3 B; Gäbler et al., 2007; Gray et al., 2007; 
Rossi et al., 2007). Notably, thymi from anti-RANKL– and 
We treated wild-type mice with either anti-RANKL or isotype 
control antibody for 2 wk and harvested their thymi for analy-
sis. Interestingly, although mice treated with anti-RANKL 
showed only a modest loss of cortical thymic epithelial cell 
(cTEC) cellularity, they exhibited a severe depletion of >80% 
of mTECs (Fig. 1 A). Using MHC II and Aire as markers of 
mTEC maturation (Gäbler et al., 2007; Gray et al., 2007), we 
further analyzed the immature mTEClo (MHC IIlo Aire), 
intermediate mTEChi (MHC IIhi Aire), and mature Aire+ 
mTEC subsets (MHC IIhi Aire+). The relative mTEC compo-
sition in anti-RANKL–treated mice revealed a substantial loss 
of Aire+ and mTEChi cells along with enrichment of the re-
maining mTEClo cells (Fig. 1 B). Although absolute numbers 
of mTECs were decreased across all mTEC subsets, mTEC 
depletion was mostly due to the loss of >90% of all Aire+ and 
mTEChi cells (Fig. 1 B). Immunostaining revealed a slight de-
crease in the density of keratin-5+ (K5) cells in the medulla of 
anti-RANKL–treated mice, whereas Aire+ cells were nearly 
undetectable (Fig. 1 C). Importantly, staining for keratin-8 
(K8) and K5 showed that the overall corticomedullary thymic 
architecture was preserved despite the loss of mature mTECs 
(Fig. 1 C). Furthermore, consistent with the loss of the Aire+ 
and mTEChi subsets, Aire-dependent TSA gene expression in 
sorted mTECs was decreased in anti-RANKL–treated mice 
(Fig. 1 D).
Next, we characterized the impact of anti-RANKL–medi-
ated mTEC depletion on thymocyte selection. In the poly-
clonal T cell repertoire of wild-type mice treated with anti- 
RANKL, we observed a modest increase in frequencies of 
both CD4 single-positive (SP) and CD8 SP thymocytes, con-
sistent with a lack of negative selection (Fig. 1 E). Importantly, 
anti-RANKL–treated mice showed only a slight reduction in 
the frequency of double-positive thymocytes while absolute 
numbers were maintained, confirming normal positive selec-
tion. In addition, total thymocyte numbers were also maintained 
in mice treated with anti-RANKL (Fig. 1 E). Furthermore, 
anti-RANKL–treated mice showed a 50% reduction of Foxp3+ 
T reg cells within the CD4 SP subset (Fig. 1 F).
Given the dramatic impact of RANKL blockade on 
mTECs, we sought to determine whether this effect could be 
reversed in the context of increased RANK signaling. Osteo-
protegerin (OPG; Tnfrsf11b) is a soluble decoy receptor for 
RANKL and its role as a negative regulator of RANK signal-
ing has been well described in bone physiology (Kearns et al., 
2008). Interestingly, in sorted wild-type mTECs, OPG ex-
pression was up-regulated in MHC IIhi mTECs when com-
pared with MHC IIlo mTECs (Fig. 2 A). To test whether 
OPG negatively regulates RANK–RANKL signaling in 
mTECs, we analyzed thymi from OPG/ mice. While cTEC 
cellularity was increased threefold in OPG/ mice, mTEC 
cellularity was increased by nearly 10-fold when compared 
with OPG+/+ mice (Fig. 2 B). Although absolute numbers of 
all mTEC subsets were increased in OPG/ mice, we ob-
served an enrichment of Aire+ mTECs and a proportional 
loss of the mTEClo subset (Fig. 2 C). Immunostaining of 
K8 and K5 showed that OPG/ thymi maintained their 
Figure 2. Increased Aire+ mTECs in OPG/ mice. (A) Quantitative 
PCR analysis of Aire and OPG gene expression in MHC IIlo and MHC IIhi 
mTECs sorted from wild-type B6 mice. Results standardized to Cyclophilin 
A and normalized to MHC IIlo, with error bars depicting mean ± SD.  
(B) Absolute numbers of mTECs and cTECs in OPG+/+ (black) and OPG/ 
(red) mice were enumerated by flow cytometry. Bar graphs of total cell 
numbers are depicted by mean ± SEM. (C) Representative flow cytometry 
plots of mTECs in B showing relative composition of indicated mTEC sub-
sets. Values depict mean ± SEM. Bar graphs (right) depict total cell num-
bers of each mTEC subset and indicate mean ± SEM. (D) Immunostaining 
for keratin-8 (green) and keratin-5 (red) on frozen thymic sections from 
OPG+/+ and OPG/ mice. Data are representative of at least three inde-
pendent experiments with at least three mice per group. *, P ≤ 0.05;  
**, P ≤ 0.01; ***, P ≤ 0.001, Student’s t test. Bars, 500 µm.
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transgenic mice express a membrane form of OVA under the 
control of the rat insulin promoter which results in its expres-
sion in both the pancreatic islets and in mTECs (Anderson et al., 
2005). When the OT-II CD4+ TCR transgenic line is crossed 
to the RIP-mOVA transgenic line, OVA-specific OT-II T cells 
are deleted in the thymus (Anderson et al., 2005). We treated 
both OT-II and OT-II x RIP-mOVA mice with either anti-
RANKL or isotype control antibody and performed thymocyte 
analysis. Consistent with previous reports, OT-II x RIP-mOVA 
mice treated with control antibody showed a significant 
isotype-treated mice at 10 wk were indistinguishable by im-
munostaining (Fig. 3 C). Thus, anti-RANKL–mediated mTEC 
depletion is a transient phenomenon with return of normal 
thymic composition after withdrawal of antibody treatment.
Manipulation of thymic negative selection  
with RANKL blockade
To further characterize the impact of anti-RANKL treatment 
on negative selection, we first used the OT-II CD4+ TCR 
x RIP-mOVA double transgenic mouse model. RIP-mOVA 
Figure 3. Regeneration of mTECs after anti-RANKL with-
drawal. (A) Experimental layout for analysis of mTEC recovery 
after anti-RANKL withdrawal. Wild-type mice were treated for  
1 wk with isotype or anti-RANKL (black arrows) and harvested at 
indicated time points (red arrows). Graph (bottom) depicts rela-
tive composition of mTEClo mTEChi and Aire+ mTECs at each time 
point in anti-RANKL–treated mice. Values represent mean  
± SEM. (B) Representative flow cytometry plot of mTECs from 
each of the indicated time points from A. Values represent the 
frequency of Aire+ mTECs. (C) Immunostaining for keratin-8 
(green) and keratin-5 (red) on thymic sections from isotype or 
anti-RANKL–treated mice harvested at 10 wk. Bars, 500 µm. 
Data shown is representative of at least two independent experi-
ments with three to five mice per group.
Figure 4. Anti-RANKL–mediated mTEC 
ablation leads to altered negative selection. 
(A) OT-II and OT-II x RIP-mOVA mice were har-
vested after 2 wk of indicated antibody treat-
ment. Percentages of CD4 SP (top) and OT-II 
clonotype-specific (bottom) thymocytes are 
shown. Values represent mean ± SD. (B) Quanti-
fication of OT-II clonotype-specific CD4 SP cells 
from A. Graph shows mean ± SEM. **, P ≤ 0.01, 
Student’s t test. (C) Representative histograms 
for Foxp3 staining in CD4 SP events from A.  
(D) Wild-type mice were treated with isotype or 
anti-RANKL antibody for 3 wk, immunized with 
P2 peptide, and then harvested 10 d later for 
tetramer analysis. Representative flow cytom-
etry plots of CD4+ T cells are shown for each 
condition. Values indicate absolute numbers of 
CD44+ P2-I-Ab–specific T cells. IRBP/ mice 
were included as positive controls. Each dot on 
the graph represents an individual mouse, bars 
show mean, and the dotted line represents the 
limit of detection. Data shown is representative 
of two to three independent experiments.  
*, P ≤ 0.05, Mann-Whitney test.
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thymus of Aire+/+ mice, whereas these cells escape deletion 
in Aire/ mice and cause autoimmune uveitis (DeVoss et al., 
2006; Taniguchi et al., 2012). Through the use of an IRBP pep-
tide class II tetramer, P2-I-Ab, such autoreactive CD4+ T cells 
can be detected in Aire/ mice. Given both the severe deple-
tion of Aire+ mTECs and the loss of thymic IRBP expression 
in anti-RANKL–treated mice, we hypothesized that P2-I-Ab–
specific T cells could be detected in treated mice. After treating 
wild-type mice with anti-RANKL antibody, we immunized 
mice with a MHC II–binding IRBP peptide epitope (P2) to 
expand T cells for detection. 10 d after immunization, lymph 
nodes and spleen were pooled for the enumeration of CD4+ 
P2-I-Ab–specific T cells by flow cytometry. Consistent with the 
loss of Aire+ mTECs, tetramer analysis of anti-RANKL–treated 
mice revealed an expansion of CD4+ P2-I-Ab–specific T cells 
reduction in the proportions of CD4 SP thymocytes and also 
had decreased frequencies and numbers of OT-II+ T cells (Fig. 4, 
A and B; Anderson et al., 2005). In contrast, thymocyte pro-
files of anti-RANKL–treated OT-II x RIP-mOVA mice were 
indistinguishable from that of OT-II mice, demonstrating that 
RANKL blockade prevented thymic deletion of OT-II T cells 
yet allowed their positive selection (Fig. 4, A and B). We also 
observed a loss of thymic T reg cell development in these 
mice, which suggested a loss of cognate antigen (OVA) ex-
pression from mTECs within the thymus (Fig. 4 C).
To expand these observations to the polyclonal T cell rep-
ertoire, we analyzed the development of Aire-dependent auto-
reactive T cells using a tetramer enrichment protocol. Previously, 
we had shown that T cells specific for the self-antigen inter-
photoreceptor retinoid-binding protein (IRBP) are deleted in 
Figure 5. RANKL blockade increases 
anti-melanoma immune response.  
(A and B) RAG1/ x TRP-1 TCR Tg mice were 
treated with isotype or anti-RANKL antibody 
for 2 wk and thymus and spleen were har-
vested for analysis. Flow cytometry plots in A 
show percentage of CD4+ (top) and CD4-gated 
V14+ (bottom) T cells. Bar graphs in B show 
quantification of data in A. Values represent 
mean ± SEM. *, P ≤ 0.05; **, P ≤ 0.01;  
***, P ≤ 0.001, Student’s t test. Data shown is 
representative of at least three independent 
experiments with n = 4–7 mice per group.  
(C) Ear skin from mice treated with isotype (gray) 
or anti-RANKL (blue) antibody was analyzed  
by qPCR for Tyrosinase and Tyrp1 expression. 
Results standardized to 2m and normalized 
to untreated B6 wild-type mice (black) with 
bars depicting mean ± SD. (D) Survival curves 
of RAG1/ x TRP-1 TCR Tg mice inoculated 
with B16 melanoma after treatment with iso-
type (gray) or anti-RANKL (blue) antibody,  
n = 7–8 mice for each group. P ≤ 0.05, Log-rank 
test. Data shown is representative of four inde-
pendent experiments. (E) Tumor sections from 
isotype or anti-RANKL–treated mice in D were 
immunostained for CD3 (pink) with DAPI coun-
terstain (purple). Bars, 50 µm. Mean densities 
of CD3+ cells per tumor area are quantified on 
the right. Four sections were evaluated for 
each treatment group and 6 imaging fields 
were randomly scored from each section. 
Graphs depict mean ± SEM. *, P ≤ 0.05, Stu-
dent’s t test. (F) RAG1/ x TRP-1 TCR Tg mice 
were inoculated with B16 melanoma after 
treatment with isotype (gray) or anti-RANKL 
(blue) antibody. Mice were harvested at 21 d 
after tumor inoculation and tumor-infiltrating 
lymphocytes (TILs) were analyzed by flow cy-
tometry. Graph depicts percentage of Foxp3+ 
CD25+ T reg cells among CD4+ T cells. Values 
represent mean ± SEM. ***, P ≤ 0.001, Student’s t test. Data shown is n = 7–9 mice per group pooled from two independent experiments. (G) Survival curves 
of RAG1/ recipients inoculated with B16 melanoma after adoptive transfer of splenocytes from either anti-RANKL (blue)– or isotype (gray)–treated 
RAG1/ x TRP-1 TCR Tg mice, n = 10 mice for each group. P ≤ 0.001, Log-rank test. Data shown is representative of two independent experiments.
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challenged with B16 melanoma, recipients of splenocytes from 
anti-RANKL–treated donors again showed a statistically sig-
nificant increase in survival (Fig. 5 G). Collectively, these data 
demonstrate that short-term, reversible RANKL blockade of 
mTEC development can be used to create a therapeutic win-
dow that allows tumor self-antigen–specific T cells to escape 
thymic deletion. Furthermore, the generation of these high-
affinity tumor-specific T cells confers a survival benefit in a 
melanoma tumor model.
In conclusion, our findings provide strong evidence that 
mTECs can be selectively and therapeutically targeted by 
RANKL blockade in adult mice and that anti-RANKL can 
be used as an approach to enhance anti-tumor responses. To 
date, previous efforts on the therapeutic manipulation of 
TECs have shown global effects that involve both cTECs and 
mTECs and disrupt thymocyte development (Fletcher et al., 
2009). The selectivity for mTECs with anti-RANKL thus 
provides evidence that central tolerance can be transiently sup-
pressed in adult hosts while maintaining T cell generation. Al-
though autoimmunity is a dangerous potential consequence 
of this approach, the treatment may also be an attractive new 
method to help break tolerance for cancer immunotherapy. 
Interestingly, although we could detect an expansion of 
retina-specific T cells in anti-RANKL–treated mice, we did 
not observe development of spontaneous uveitis (unpublished 
data), suggesting that this brief window of central tolerance 
suppression was countered by peripheral tolerance mecha-
nisms such as T reg cells which existed before treatment. Im-
portantly, we find that the medullary epithelial compartment 
of the thymus recovers after withdrawal of anti-RANKL an-
tibody and, thus, only a transient window of central tolerance 
suppression occurs. This window may be an attractive feature 
of this approach, especially if coupled with methods that pref-
erentially expand tumor-specific T cells over pathogenic auto-
reactive T cells. Currently, there has been intense interest and 
progress in manipulating peripheral tolerance for immuno-
therapy (Chen and Mellman, 2013). Given our results, it will 
also be of interest to determine if a combination of methods 
that target both central and peripheral tolerance could fur-
ther enhance anti-tumor immune responses. Finally, it is impor-
tant to note that our results also have implications for patients 
in the clinical setting receiving denosumab, a humanized mono-
clonal antibody that blocks RANKL which is widely used in 
the treatment of osteoporosis in adults (Cummings et al., 2009). 
Further study will be needed in such patients regarding their 
susceptibility to autoimmunity and for other potential defects 
in central tolerance.
MATERIALS AND METHODS
Mice. C57BL/6, B6.RAG1/ Tyrp1B-w TRP-1 TCR transgenic, and B6.
OPG/ mice were purchased from The Jackson Laboratory. Mice were 
treated intraperitoneally with 100 µg anti-RANKL (IK22/5) or isotype con-
trol (2A3; Bio X Cell) antibody three times per week as stated in the text. 
B6.OT-II, B6.RIP-mOVA, and B6.IRBP/ mice were described previously 
(Anderson et al., 2005; DeVoss et al., 2006). Mice were treated at 3–5 wk of 
age and harvested at time points indicated in the text. All mice were housed 
and bred in specific pathogen-free conditions in animal facilities at UCSF or 
(Fig. 4 D). Overall, these data show a clear defect in negative 
selection associated with the loss of Aire+ mTECs in anti-
RANKL–treated mice.
Treatment with anti-RANKL enhances anti-tumor immunity
Given its ability to selectively block mTECs and central toler-
ance, we next sought to determine whether anti-RANKL 
treatment could be used to therapeutically enhance anti-tumor 
immunity. Previous work has shown that many tumor self-
antigens are expressed by mTECs as TSAs, and that high-affinity 
T cells capable of recognizing these tumor self-antigens are ef-
ficiently deleted in the thymus (Bos et al., 2005; Träger et al., 
2012; Zhu et al., 2013). To test whether anti-RANKL treat-
ment could rescue tumor self-antigen–specific T cells from 
thymic deletion, we used the TRP-1 CD4+ TCR transgenic 
mouse model which generates T cells specific for the mela-
noma antigen TRP-1 (Tyrp1; Muranski et al., 2008). TRP-1 is 
expressed in B16 melanoma cells, and TRP-1 T cells are effica-
cious against established B16 melanoma tumors (Muranski et al., 
2008). Importantly, mTECs endogenously express TRP-1 in an 
Aire-dependent manner, such that TRP-1–specific T cells are 
deleted in the thymi of Aire-sufficient, TRP-1–sufficient hosts 
(Muranski et al., 2008; Zhu et al., 2013). Given the depletion of 
Aire+ mTECs and loss of thymic TRP-1 expression in anti-
RANKL–treated mice (Fig. 1 D), we hypothesized that anti-
RANKL treatment could rescue TRP-1 T cells from thymic 
deletion. We treated RAG1/ x TRP-1 TCR transgenic mice 
with either anti-RANKL or control antibody and harvested 
their thymi and spleens for analysis. Consistent with previous 
reports, isotype-treated mice showed efficient deletion of CD4 
SP T cells in the thymus (Fig. 5 A; Muranski et al., 2008; Zhu 
et al., 2013). In contrast, anti-RANKL treatment prevented 
deletion of CD4 SP cells and also resulted in a much higher 
percentage of V14+ T cells (Fig. 5, A and B). Furthermore, 
TRP-1 T cells were detectable in the spleens of anti-RANKL–
treated mice and also expressed higher levels of the V14 TCR 
(Fig. 5, A and B). In addition, qPCR analysis revealed a loss of 
Tyrosinase and Tyrp1 expression in the ear skin of anti-RANKL–
treated mice which appeared consistent with the destruction of 
melanocytes by TRP-1 T cells (Fig. 5 C).
Next, we challenged anti-RANKL–treated RAG1/ x 
TRP-1 mice with B16 melanoma to determine whether a lim-
ited break in central tolerance could improve overall survival. 
We observed a statistically significant increase in the survival of 
anti-RANKL–treated mice compared with the isotype-treated 
cohort (Fig. 5 D). We also found evidence of an enhanced T cell 
response in anti-RANKL–treated mice by measuring CD3+ 
T cell infiltrates within the tumors of these mice (Fig. 5 E). Of 
note, given the overall increase in T reg cells in the spleen and 
tumors of anti-RANKL–treated mice, it appears unlikely that 
the survival benefit observed in TRP-1 mice is due to differ-
ences in T reg cell numbers (Fig. 5, B and F). Furthermore, to 
exclude potential effects of anti-RANKL antibody on the 
tumor microenvironment, we performed adoptive transfer 
studies in which splenocytes from antibody-treated RAG1/ 
x TRP-1 mice were transferred into RAG1/ mice. When 
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